Skip to main content

Advances in Host-Directed Therapies Against Tuberculosis

  • Book
  • © 2021


  • Host-directed therapy is a unique, innovative, and burgeoning new approach for the treatment of infectious diseases, and specifically for tuberculosis, the leading cause of death by a single infectious agent. As a new field, no similar comprehensive survey of completed and ongoing research exists

  • Each section of the text contains several chapters written by a top expert in that specific area. The information provided represents a thorough and state-of-the-art analysis of the field

  • The implications for host responses and pathways are of broad interest in physiology and in various diseases of non-infectious origin (e.g, autoimmunity, cancer, metabolic disorders), or those that can be exploited for treating infectious diseases other than tuberculosis

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

About this book

This book discusses specific immune cell regulatory  pathway(s), immune cell types,  or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

Similar content being viewed by others


Table of contents (22 chapters)

  1. Introduction

  2. Targeting Immunometabolism

  3. Enhancing Anti-mycobacterial Mechanisms

  4. Targeting Immune Cells

Editors and Affiliations

  • Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, USA

    Petros C. Karakousis

  • Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, Rockville, USA

    Richard Hafner

  • Public Health Research Institute New Jersey Medical School Rutgers Biomedical and Health Sciences, Rutgers-The State University of New Jersey, Newark, USA

    Maria Laura Gennaro

About the editors

Petros C. Karakousis, M.D., is an infectious diseases-trained physician scientist and Professor of Medicine at the Johns Hopkins University School of Medicine. His research focus is on host-pathogen interactions contributing to Mycobacterium tuberculosis persistence and antibiotic tolerance. His laboratory is actively investigating the repurposing of clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology.

Maria Laura Gennaro, M.D., is Professor of Medicine at Rutgers New Jersey School of Medicine. Her laboratory studies mechanisms of adaptation expressed by Mycobacterium tuberculosis and by the host macrophage during infection, with the goal of finding targets for therapeutic intervention. She has a specific interest in macrophage lipid metabolism, which is altered following M. tuberculosis infection, thereby promoting bacterial survival.

Richard Hafner, M.D., is an infectious diseases-trained physician and Chief of the TB Clinical Research Branch in the Division of AIDS at NIAID/NIH. Throughout his career, he has had a long-standing interest in advancing innovative host-directed therapies for infections. He has been involved in several clinical trials, authored various articles, and hosted multiple scientific meetings related to research to develop targeted HDTs for TB.

Bibliographic Information

  • Book Title: Advances in Host-Directed Therapies Against Tuberculosis

  • Editors: Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro

  • DOI:

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Nature Switzerland AG 2021

  • Hardcover ISBN: 978-3-030-56904-4Published: 04 December 2020

  • Softcover ISBN: 978-3-030-56907-5Published: 04 December 2021

  • eBook ISBN: 978-3-030-56905-1Published: 03 December 2020

  • Edition Number: 1

  • Number of Pages: XIII, 332

  • Number of Illustrations: 20 b/w illustrations

  • Topics: Immunology, Infectious Diseases, Pharmacotherapy

Publish with us